MASP-2 Inhibitor Targets Lectin Pathway for Renal Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrosis and inflammation-related diseases, such as renal fibrosis, lack effective therapeutic agents, and existing anti-inflammatory agents have minimal clinical impact, highlighting the need for targeted therapies that can inhibit or reverse fibrotic tissue damage.
Innovation Solution
Administering a MASP-2 inhibitory agent, specifically a MASP-2 antibody or fragment, that selectively inhibits the lectin pathway complement activation without affecting the classical pathway, to treat or prevent fibrosis and inflammation in various diseases, including renal fibrosis and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If C5 is blocked using Eculizumab, then complement activation is inhibited downstream, but the initiation steps of complement activation remain unaffected and fibrosis progression continues
Solution Approach 1:
The patent segments the complement system into upstream initiation steps (C1q, C2, C4) and downstream effector molecules (C5, C3). By targeting the upstream initiation steps with MASP-2 inhibitors, the patent achieves more effective fibrosis treatment compared to downstream C5 blocking alone, resolving the contradiction between complement inhibition and fibrosis treatment efficacy.
Solution Approach 2:
The patent applies preliminary action by inhibiting the initiation steps of complement activation (C1q, C2, C4) before the downstream effector molecules are activated. This preliminary inhibition prevents the cascade from starting, thereby more effectively preventing fibrosis progression compared to blocking only the downstream C5 step.
2Object-affected harmful factors
If classical pathway complement activation is inhibited, then fibrosis is reduced, but host defense against microbial infection is compromised
Solution Approach 1:
The patent applies local quality by selectively inhibiting the lectin pathway (via MASP-2) while preserving the classical pathway's ability to respond to microbial infections. This selective inhibition allows the system to have different properties in different contexts: anti-fibrotic activity when needed, and immune defense when pathogens are present.
Solution Approach 2:
The patent uses MASP-2 as an intermediary target that mediates between the lectin pathway and the fibrosis process. By blocking MASP-2, the patent creates a selective pressure that reduces fibrosis while maintaining classical pathway functionality for infection defense, as MASP-2 is specific to the lectin pathway and not involved in classical pathway-mediated immune responses.
3Productivity
If lectin pathway complement activation is selectively inhibited, then fibrosis progression is halted, but the complexity of complement regulation increases
Solution Approach 1:
The patent extracts and isolates the MASP-2 component from the broader complement system, creating a specific inhibitory target that can be addressed independently. By focusing on MASP-2 as a discrete target, the patent simplifies the regulatory approach compared to attempting to control the entire complement cascade, thereby reducing the practical complexity of therapy while maintaining effective fibrosis inhibition.
Data Source
AI summary
In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.